Project cooperationUpdated on 17 December 2025

In Vitro 3D Immunospheroids

Miguel Servet Researcher at INIBIC

A Coruña, Spain

About

Traditional two-dimensional (2D) monoculture models, commonly used for in vitro screenings, present significant limitations for evaluating new therapies. These models fail to faithfully reproduce the complexity of the TME, as they do not allow for the study of critical cellular interactions, such as the interaction of the cancer cells with macrophages, or capture the conditions of a physiological 3D architecture. This fundamental gap often leads to discrepancies between experimental and clinical results. Thus, we use 3D immunospheroid in vitro tumor models, including cancer cells and primary human macrophages and/or T cells, to precisely study tumor-immune interactions, analyze signalling mechanisms in treatment response and resistance (e.g., to anti-HER2 or anti-EGFR therapies), and evaluate drug penetration within a physiologically relevant 3D environment, bridging the gap toward effective personalized clinical strategies.

Topic

DESTINATION 4: HORIZON-HLTH-2026-01-CARE-01: Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalised approaches
DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies

Similar opportunities

Project cooperation
Myeloid cell therapy
- DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
Fernando Torres Andón
Miguel Servet Researcher at INIBIC
A Coruña, Spain
Project cooperation
Cancer, Fibrosis and Coagulation
- Consortium/Coordinator seeks Partners
- Partner seeks Consortium/Coordinator
- DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
Alessandra Metelli
Researcher at IRCCS Regina Elena National Cancer Institute
Rome, Italy
Project cooperation
Organ on chips, organoids and other NAMs for biomedical research
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
Joude Cachoux
Business Development Manager, PharmD, MPH at LEITAT
Barcelona, Spain